ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

19.12 0.59 −2.99%
Market cap
$3.4B
P/E
8.5×
Fwd P/E
55.6×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
35.74% 37.32% 39.89% 34.95%

+8 more TTM periods

Piotroski F-Score
5 5 6 6
ROA
25.64% 27.44% 28.42% 22.64%
ROIC
15.42% 12.75% 16.07% 214.34%
Return on Tangible Assets
43.23% 46.66% 49.34% 36.10%
Average Days of Receivables
53.32 49.45 50.49 48.60
Free Cash Flow per Share
0.85 0.67 0.62 0.00
Free Cash Flow
145.63 113.59 104.69 0.06
Capital Expenditures
(14.69) (9.90) (5.14) (198.88)
Other line items
Cash ROIC
6.43% 5.41% 5.11% 0.00%
Accounts Receivable Turnover
7.96 8.36 8.47 8.38
Accounts Payable Turnover
3.12 6.16 6.57 4.14
Inventory Turnover
3.45 3.43 3.14 1.88
Average Days of Payables
161.09 47.86 44.72 93.85
Days of Inventory on Hand
117.01 123.39 142.19 125.57
Tax Rate
2.14 2.26 1.81 (0.05)
Research and Development Expense of Revenue
29.07% 29.89% 30.69% 32.93%
Selling, General and Administrative Expense of Revenue
54.48% 54.19% 51.23% 49.98%
Share Based Compensation of Revenue
5.10% 5.06% 4.87% 4.71%
Operating CF/Net income
0.42 0.33 0.28 0.76
Depreciation/Fixed assets
0.57 0.55 0.84 1.75
Capex/Depreciation
(1.51) (1.23) (0.81) (30.70)
Revenue per Share
6.64 6.42 6.36 6.20
Operating CF per Share
0.93 0.72 0.65 1.18
Capex per Share
(0.09) (0.06) (0.03) (1.18)
Capex to Sales
0.01 0.01 0.00 0.19

Fold the line items

Columns are period end dates